SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a late stage developer of therapies for cancer and applications using electroporation to deliver gene-based treatments, announced today that it will receive an appropriation of $1.1 million from the United States Department of Defense to develop applications of its electroporation-based gene delivery technology for vaccination against infectious diseases including potential bioterrorism agents. The United States Congress appropriated the funding in the Defense Appropriations Bill for 2007. The appropriation is a continuation of prior funding from the United States Army to Inovio focused on the development of a more effective gene delivery system for gene-based vaccines. Inovio is working closely on this project with Dr. Connie Schmaljohn, a world-renowned virologist and chief of the Department of Molecular Virology at the United States Army Medical Research Institute of Infectious Diseases, USAMRIID, at Ft. Detrick, Maryland.
